`

Tagged: Strategic Clinical Innovation Organization

SCIO assists with early stage biotech company evaluation. Learn why adopting this clinical roadmap and development strategy is critical to your success in bringing your product to market.

October 28th, 2022 | Strategic Clinical Innovation Organization

How can SCIO SM help? To enhance your position, it becomes crucial to demonstrate that your product/technology is the “safe” option for investment and a stand-out opportunity by including a clinical roadmap and development strategy of your product/technology. This roadmap illuminates clearly for the investment team what the target indications will be and the paths […]

Orphan drug designation provides key incentives of the ODA, including significant tax credits for qualified clinical testing. The BBCR team will empower sponsors with medical insight, ODA application experience, strategic clinical plan, and streamlined trials design.

October 12th, 2022 | Strategic Clinical Innovation Organization

Developing drugs with substantial benefits in smaller, molecularly defined, pharmacologically relevant subpopulations of patients with the same clinically recognized disease is increasingly being viewed as a viable pathway for bringing drugs to market.    

BBCR supports innovative and repurposing treatments for orphan diseases.

October 4th, 2022 | Strategic Clinical Innovation Organization

Developing innovative or repurposing drugs for orphan diseases can be rewarding, but navigating the challenges is not for the faint of heart. Expert guidance is essential in an area where patients are few; a lack of previous studies may hamper progress as you mount an orphan petition and negotiate a clinical plan with the FDA. […]

BBCR provides expert development guidance for Orphan Disease. The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap.

September 28th, 2022 | Strategic Clinical Innovation Organization

As one of the first consultancy teams to streamline clinical trials, BBCR’s boutique consulting team specializes in rare disease and orphan indications dedicated to supporting pharmaceutical innovators, and nurturing each product’s strengths. The BBCR Team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment Clinical strategy for […]

An attractive option of drug repurposing is to use a scientific approach to identify new uses for existing drugs thereby reducing the need for early stage clinical trials.

August 17th, 2022 | Strategic Clinical Innovation Organization

People tend to believe that a repurposed therapy can never be truly novel or transformative. Nothing could be further from the truth. About a third of orphan approvals by the FDA since the program began have been mostly for repurposed mass-market drugs. BBCR’s team of industry experts can help match treatments to rare genetic conditions […]

BBCR meets clients’ needs in the fast paced and ever-changing regulatory environment. As specialists in Orphan and Personalized Medicine, BBCR helps clients identify areas of need or economic interest and helps them find homes for treatments for rare diseases and precision medicine.

August 10th, 2022 | Strategic Clinical Innovation Organization

BBCR helps orphan drug developers find direction in clinical trials involving biologics, biosimilars, small molecules, medical devices, and repurposing. BBCR consultants have the experience to guide you through the development process with a clinical plan and a regulatory strategy. Our team will empower you with medical insight, effective regulatory expertise, strategy, and streamlined early clinical […]

BBCR specializes in rare disease, working with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process in order to achieve optimal product market positioning.

July 27th, 2022 | Strategic Clinical Innovation Organization

Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements. Click the button below to learn more about how we have helped companies with their clinical trial needs.    

SCIO helps early stage biotech company evaluation. Learn why adopting this clinical roadmap and development strategy is critical to your success in bringing your product to market.

April 20th, 2022 | Strategic Clinical Innovation Organization

How can SCIO help? To enhance your position, it becomes crucial to demonstrate that your product/technology is the “safe” option for investment and a stand-out opportunity by including a clinical roadmap and development strategy of your product/technology. This roadmap illuminates clearly for the investment team what the target indications will be and the paths to […]

BBCR has extensive experience in biologics for rare diseases and can assist with the development of a targeted strategy to meet your study needs.

April 12th, 2022 | Strategic Clinical Innovation Organization

Biologic treatments show promise in providing clinical solutions to a variety of diseases including rare cancers and precision medicine. Related Services Include: Indications analysis and prioritization Strategic drug assessment Clinical study design and protocol Biomarker strategy Early Clinical Development FDA meeting and submission Pre-ND integrated development plan CRO and project management Study remediation and rescue

BBCR consultants have the experience to guide you through the development process with a clinical plan and a regulatory strategy. We invite to reach out to learn more.

December 29th, 2021 | Strategic Clinical Innovation Organization

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. We understand that navigating the rare disease development process requires expert guidance. BBCR can assist in the following areas: Biologics Biosimilars Small Molecules Medical Devices Drug Repurposing Why the SCIO? Clinical trials are […]

Pin It on Pinterest